Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NRBO NeuroBo Pharmaceuticals
1.391
-0.139-9.08%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
-10.39% 3.1M -18.01% 3.22M -13.66% 2.88M -48.52% 15.3M
Selling and administrative expenses
22.37% 2.53M 16.88% 2.24M -10.61% 1.96M 11.55% 8.75M
-General and administrative expense
22.37% 2.53M 16.88% 2.24M -10.61% 1.96M 11.55% 8.75M
Research and development costs
-59.04% 571K -51.19% 982K -19.51% 920K -70.07% 6.55M
Operating profit
10.39% -3.1M 18.01% -3.22M 13.66% -2.88M 48.52% -15.3M
Net non-operating interest income expense
0 0 0 -64.10% 14K
Non-operating interest income
-- 0 -- 0 -- 0 -- 14K
Other net income (expense)
-9K -84K
Other non- operating income (expenses)
-- -9K -- -84K -- -- -- --
Income before tax
10.05% -3.11M 15.76% -3.3M 13.51% -2.88M 48.50% -15.28M
Income tax
0 0 0 0
Net income
10.05% -3.11M 15.76% -3.3M 13.51% -2.88M 48.50% -15.28M
Net income continuous Operations
10.05% -3.11M 15.76% -3.3M 13.51% -2.88M 48.50% -15.28M
Minority interest income
Net income attributable to the parent company
10.05% -3.11M 15.76% -3.3M 13.51% -2.88M 48.50% -15.28M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
10.05% -3.11M 15.76% -3.3M 13.51% -2.88M 48.50% -15.28M
Basic earnings per share
27.08% -3.5 33.33% -3.6 26.67% -3.3 63.93% -19.8
Diluted earnings per share
27.08% -3.5 33.33% -3.6 26.67% -3.3 63.93% -19.8
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist